Aligos Therapeutics Completes Enrollment In The ALG-055009 Phase 2a HERALD Study For The Treatment Of MASH
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics has completed enrollment in the Phase 2a HERALD study for ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). Topline data is expected in early Q4 2024, with Dr. Rohit Loomba serving as Principal Investigator.
May 21, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aligos Therapeutics has completed enrollment in its Phase 2a HERALD study for ALG-055009, targeting MASH. Topline data is expected in early Q4 2024, which could significantly impact the company's stock price depending on the results.
The completion of enrollment in a Phase 2a study is a significant milestone for a clinical-stage biopharmaceutical company. The anticipation of topline data in early Q4 2024 could create positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100